We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
-10.9%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$44.9M
AUM Growth
–
Cap. Flow
+$51.3M
Cap. Flow %
114.19%
Top 10 Hldgs %
67.05%
Holding
22
New
22
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
DVA icon
DaVita
DVA
+$4.36M
2
DGX icon
Quest Diagnostics
DGX
+$4.23M
3
EW icon
Edwards Lifesciences
EW
+$3.99M
4
FOLD
Amicus Therapeutics
FOLD
+$3.65M
5
CNC icon
Centene
CNC
+$3.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 84.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVA icon
1
DaVita
DVA
$15.1B
$4.07M 9.07%
+56,290
New +$4.36M
EW icon
2
Edwards Lifesciences
EW
$47.6B
$3.92M 8.73%
+165,444
New +$3.99M
DGX icon
3
Quest Diagnostics
DGX
$25.1B
$3.72M 8.29%
+60,520
New +$4.23M
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$3.26M 7.26%
+232,957
New +$3.65M
NVRO
5
DELISTED
NEVRO CORP.
NVRO
$2.86M 6.37%
+61,660
New +$2.99M
CNC icon
6
Centene
CNC
$31.3B
$2.75M 6.13%
+101,568
New +$3.4M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$35.9B
$2.71M 6.05%
+48,085
New +$3.12M
SYK icon
8
Stryker
SYK
$127B
$2.61M 5.82%
+27,781
New +$2.75M
MDXG icon
9
MiMedx Group
MDXG
$626M
$2.22M 4.94%
+229,839
New +$2.43M
NBIX icon
10
Neurocrine Biosciences
NBIX
$17.7B
$1.97M 4.39%
+49,500
New +$2.39M
ENDP
11
DELISTED
Endo International plc
ENDP
$1.84M 4.11%
+26,600
New +$2.13M
BMY icon
12
Bristol-Myers Squibb
BMY
$127B
$1.77M 3.94%
+29,900
New +$1.9M
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
$1.52M 3.39%
+85,834
New +$1.55M
CLVS
14
DELISTED
Clovis Oncology, Inc.
CLVS
$1.51M 3.37%
+16,458
New +$1.42M
SGNT
15
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$1.41M 3.15%
+92,213
New +$1.99M
IPXL
16
DELISTED
Impax Laboratories, Inc.
IPXL
$1.35M 3%
+38,279
New +$1.72M
VNDA icon
17
Vanda Pharmaceuticals
VNDA
$312M
$1.34M 2.98%
+118,707
New +$1.45M
XNPT
18
DELISTED
XENOPORT, INC.
XNPT
$1.28M 2.85%
+368,395
New +$2.33M
ANAC
19
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$1.1M 2.45%
+9,349
New +$1.22M
SGYP
20
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.08M 2.4%
+203,155
New +$1.57M
PEN icon
21
Penumbra
PEN
$12.5B
$400K 0.89%
+9,980
New +$404K
EPRS
22
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$189K 0.42%
+42,787
New +$251K

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q3 2015 Portfolio in Review

Q3 2015 is the first quarter with a 13F filing on record for Asymmetry Capital Management, which disclosed 22 positions worth $44.9M. Its ten largest holdings account for 67% of the portfolio.

Its largest position is DaVita: 56,290 shares worth $4.07M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets.

  • Asymmetry Capital Management's largest Q3 2015 buy was DaVita: 56,290 shares worth $4.07M.
  • Asymmetry Capital Management's ten largest holdings make up 67% of its $44.9M portfolio in Q3 2015.
  • Asymmetry Capital Management disclosed 22 positions in Q3 2015, its first 13F filing on record.

Based on Asymmetry Capital Management's 13F filing for Q3 2015, filed 9 Nov 2015.